Shilpa Gupta, MD, Cleveland Clinic

Articles

Dr Gupta on Avelumab Maintenance in Urothelial Carcinoma With/Without Diabetes Mellitus

November 5th 2025

Shilpa Gupta, MD, discusses data from a subgroup analysis of the phase 3 JAVELIN Bladder 100 and future questions surrounding the use of avelumab maintenance in this setting.

Dr Gupta on Future Directions With Enfortumab Vedotin/Pembrolizumab in Urothelial Carcinoma

October 29th 2025

Shilpa Gupta, MD, discusses future research directions for enfortumab vedotin plus pembrolizumab in urothelial carcinoma.

Dr Gupta on Responses With Enfortumab Vedotin/Pembrolizumab in Urothelial Carcinoma

October 22nd 2025

Shilpa Gupta, MD, discusses response and subgroup data with enfortumab vedotin plus pembrolizumab in locally advanced/ metastatic urothelial carcinoma.

Dr Gupta on the Efficacy of Enfortumab Vedotin Plus Pembrolizumab in Urothelial Carcinoma

October 15th 2025

Shilpa Gupta, MD, discusses the clinical effects of findings from the phase 3 EV-302/KEYNOTE-A39 trial in locally advanced/metastatic urothelial carcinoma.

Dr Gupta on Avelumab Maintenance Therapy in Advanced Urothelial Cancer With Diabetes

March 21st 2025

Shilpa Gupta, MD, discusses OS outcomes with first-line maintenance avelumab plus BSC in advanced urothelial carcinoma based on diabetes mellitus.

Dr Gupta on Updated Data With Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

February 16th 2025

Shilpa Gupta, MD, discusses updated data with enfortumab vedotin plus pembrolizumab in previously untreated urothelial carcinoma.

Key Takeaways on Evolving Bladder Cancer Treatment Landscape

December 21st 2023

The expert panel concludes its discussion by providing key takeaways on the evolving bladder cancer treatment landscape following ESMO 2023.

Approach to Collaborative Care in Bladder Cancer

December 21st 2023

The panel discusses the Large Urology Group Practice Association and provides insights on collaborative care approaches in bladder cancer.

Enfortumab Vedotin and the Role of ADCs in Bladder Cancer

December 15th 2023

Bladder cancer specialists discuss enfortumab vedotin and the role of antibody-drug conjugates in the treatment landscape.

Bladder Cancer: Highlights from ESMO 2023 and Ongoing Developments

December 15th 2023

The expert panel reviews highlights from ESMO 2023 and discusses ongoing developments in the treatment landscape for bladder cancer.

Bladder Cancer: Treatment Options and Managing Adverse Effects

December 7th 2023

Comprehensive insights on treatment considerations and managing immunotherapy-related adverse effects for patients with bladder cancer.

Monitoring Patients With NMIBC

December 7th 2023

The panel discusses strategies for monitoring patients with non–muscle invasive bladder cancer and the potential role of biomarkers.

Treatment Considerations and Role of Trimodal Therapy in Bladder Cancer

November 30th 2023

Expert perspectives on treatment options available for patients with bladder cancer and the role of trimodal therapy.

Overview of Non–Muscle Invasive Bladder Cancer (NMIBC)

November 30th 2023

A panel of experts on bladder cancer provide an overview of the stratification, natural history, and treatment of bladder cancer.

Dr Gupta on Criteria for the EV-103 Trial in Advanced Urothelial Cancer

July 13th 2023

Shilpa Gupta, MD, discusses the enrollment criteria used for the phase 1/2 EV-103 trial in patients with locally advanced or metastatic urothelial carcinoma, and highlights next steps for the investigation of the frontline combination of enfortumab vedotin and pembrolizumab in the phase 3 EV-302 trial.

Dr Gupta on the MAIN-CAV Trial of Maintenance Cabozantinib Plus Avelumab in mUC

June 27th 2023

Shilpa Gupta, MD, discusses the design, methodology, and potential significance of the ongoing phase 3 MAIN-CAV trial in patients with locally advanced/metastatic urothelial carcinoma

Dr Gupta on the 4-Year Efficacy of the EV-103 Trial in Urothelial Carcinoma

June 15th 2023

Shilpa Gupta, MD, discusses the 4-year safety and efficacy data derived from the phase 1/2 EV-103 trial in patients with locally advanced or metastatic urothelial carcinoma.

Dr Gupta on Anticipated Real-world Benefit of the JAVELIN Bladder 100 Trial in Urothelial Carcinoma

June 2nd 2023

Shilpa Gupta, MD, discusses the real-world benefit that may be derived based on findings from the long-term analysis of the phase 3 JAVELIN Bladder 100 trial in patients with advanced urothelial carcinoma.

Dr Gupta on the Background of the JAVELIN Bladder 100 Trial in Urothelial Carcinoma

May 18th 2023

Shilpa Gupta, MD, discusses the background of the phase 3 JAVELIN Bladder 100 trial in patients with advanced urothelial carcinoma.

Novel Therapy in Urothelial Carcinoma: An Evolving Treatment Landscape

May 18th 2023

Closing out their discussion on urothelial carcinoma, key opinion leaders share clinical pearls and excitement for the evolving treatment landscape.